Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
CRISPR Therapeutics AG, a pioneering biotechnology company headquartered in Switzerland (CH), is at the forefront of gene editing innovation. Founded in 2013, the company focuses on developing transformative therapies using its proprietary CRISPR/Cas9 technology, which allows for precise modifications to DNA.
With a strong presence in Europe and North America, CRISPR Therapeutics is dedicated to addressing serious diseases, particularly in the fields of oncology, regenerative medicine, and genetic disorders. Its lead product candidates, including CTX001 for sickle cell disease and beta-thalassemia, exemplify the unique potential of CRISPR technology to provide curative solutions.
Recognised for its significant contributions to the industry, CRISPR Therapeutics AG continues to solidify its market position through strategic partnerships and groundbreaking research, making it a key player in the rapidly evolving landscape of gene editing therapies.
-16 vs industry average
CRISPR Therapeutics AG’s score of 26 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for CRISPR Therapeutics AG yet.
CRISPR Therapeutics AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse.
In terms of climate commitments, CRISPR Therapeutics AG has not outlined any formal reduction targets or initiatives. There are no details available regarding Science-Based Targets Initiative (SBTi) commitments or other climate pledges. This lack of publicly available data suggests that the company may still be in the early stages of developing a comprehensive climate strategy.
As the biotechnology industry increasingly prioritises sustainability, CRISPR Therapeutics AG's future climate commitments will be crucial for aligning with industry standards and expectations.
No climate goals have been disclosed for CRISPR Therapeutics AG yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more